ALPS Advisors
DSGN icon

ALPS Advisors’s Design Therapeutics DSGN Stock Holding History

ALPS Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.04M Buy
82,927
+19,536
+31% +$270K ﹤0.01% 665
2026
Q2 		$917K Buy
63,391
+13,182
+26% +$164K ﹤0.01% 721
2026
Q1 		$534K Buy
50,209
+3,438
+7% +$34.8K ﹤0.01% 710
2025
Q4 		$439K Buy
+46,771
New +$366K ﹤0.01% 830

Other funds holding DSGN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

ALPS Advisors's DSGN Position: Q3 2026 in Review

ALPS Advisors increased its Design Therapeutics (DSGN) stake by 31% in Q3 2026, buying an estimated $270K and bringing the position to 82,927 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #665.

ALPS Advisors first reported a position in DSGN in Q4 2025 and has held it in 4 quarters since. 54 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • ALPS Advisors held 82,927 shares of Design Therapeutics worth $1.04M as of Q3 2026.
  • ALPS Advisors bought 19,536 Design Therapeutics shares in Q3 2026, an estimated $270K.
  • Design Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #665 holding.
  • ALPS Advisors first reported a position in Design Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 54 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.